Lead Time of Prostate Cancer Detected in Population Based Screening for Prostate Cancer in Japan

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1258-1264

  Ito, Kazuto ^a   Yamamoto, Takumi ^a   Miyakubo, Mai ^a   Takechi, Hiroyuki ^a   Ohi, Masaru ^a   Shibata, Yasuhiro ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

bias (epidemiology); mass screening; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; DIGITAL RECTAL EXAMINATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES;

AGED; AMBULATORY CARE; BIAS (EPIDEMIOLOGY); ENDOSONOGRAPHY; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548406469     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.144     Document Type: Article

References (17)

1. Labrie F., Candas B., Dupont A., Cusan L., Gomez J.L., Suburu R.E., et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 (1999) 83
2. Bartsch G., Horninger W., Klocker H., Reissigl A., Oberaigner W., Schonitzer D., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Tyrol Prostate Cancer Screening Group. Urology 58 (2001) 417
3. Meyer F., Meyer F., Moore L., Bairati I., and Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 161 (1999) 1189
4. Prorok P.C., Andriole G.L., Bresalier R.S., Buys S.S., Chia D., Crawford E.D., et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Control Clin Trials 21 suppl (2000) 273S
5. Schröder F.H., Kranse R., Rietbergen J., Hoedemaeke R., and Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 35 (1999) 539
6. Standaert B., and Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 80 (1997) 1830
7. deKoning H.J., Liem M.K., Baan C.A., Boer R., Schröder F.H., and Alexander F.E. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. ERSPC. Int J Cancer 98 (2002) 268
8. Smart C.R. Prostate cancer facts and fiction. J Surg Oncol 66 (1997) 223
9. Pearson J.D., and Carter H.B. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 152 (1994) 1743
10. Ries L.A.G., Kosary C.L., and Hankey B.F. SEER Cancer Statistics Review, 1973-1995 (1998), National Cancer Institute, Bethesda, Maryland
11. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283
12. Gustafsson O., Norming U., Almgard L.E., Fredriksson A., Gustavsson G., Harvig B., et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 148 (1992) 1827
13. Holmberg L., Bill-Axelson A., Helgesen F., Salo J.O., Folmerz P., Haggman M., et al. Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781
14. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977
15. Bosch J.L., Hop W.C., Kirkels W.J., and Schröder F.H. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 75 (1995) 622
16. Yu X., Han M., Gashti S.N., Yeh J.T., Roehl K.A., and Catalona W.J. Comparison of different methods for calculating PSA velocity: importance of time interval prior to diagnosis of prostate cancer. J Urol 173 suppl (2005) 128 abstract 469.
17. Kubota Y., Ito K., Imai K., and Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 50 (2002) 262